CASI Pharmaceuticals, Inc. announced that Wei-Wu He, Ph.D., Executive Chairman of CASI, has been appointed Chief Executive Officer. Dr. He will continue to serve as Chairman of the Board of Directors. Dr. He succeeds Ken K. Ren, Ph.D. who for personal reasons is stepping down from his role as Chief Executive Officer but will remain on the Company's Board of Directors.

Prior to joining CASI as CEO, Dr. He had a very successful career building companies from early to revenue and profit stages. Most recent from his track record was serving as CEO of OriGene Technologies, Inc. In addition, as a result of the management changes and the company's focus on growing its commercial operations in China, the company expects that Cynthia W. Hu, COO, General Counsel & Secretary, will have a reduced policy making role in the future. Ms. Hu will retain her title and continue as General Counsel and Secretary and concentrate on operational matters in the United States.

Ms. Hu will not be an “officer” for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.